CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 73 enrolled
Drug / intervention
Oxycodonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03176121
NCT03176121Phase 4Completed
CompareCT.gov

A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain

Taiwan Mundipharma Pharmaceuticals Ltd.·interventional·Posted Jun 5, 2017·Updated Mar 18, 2020

In Brief

A Phase 4 clinical trial evaluating Oxycodone for Cancer and Pain. Completed, enrolled 73 participants across 10 sites.

Detailed Summary

This study is to evaluate the safety and tolerability of oxycodone control-released (CR) and/or immediate-released (IR) use in patients with moderate to severe cancer pain in a 3-months period in Taiwan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Pain
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 5, 2017
Enrollment StartOct 31, 2016
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.1 years ago

Interventions

Oxycodonedrug

Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.